1. Indexing: the north face

   • Jean-François Morère

   Editorial 06 May 2009 Pages: 63 - 63

2. The toxicities of modern targeted therapies—learning from the price of progress

   • Francis J. Giles

   Editorial 09 April 2009 Pages: 65 - 66

3. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors

   • Kelly L. Snider
   • Michael L. Maitland

   Review 17 April 2009 Pages: 67 - 76

   

4. Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?

   • Evandro de Azambuja
   • Philippe L. Bedard
   • Martine Piccart-Gebhart

   Review 06 May 2009 Pages: 77 - 88

   

5. QT interval prolongation among patients treated with angiogenesis inhibitors

   • Stephane Ederhy
   • Ariel Cohen
   • Jean-Charles Soria

   Review 06 May 2009 Pages: 89 - 97

   

6. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

   • Kevin Kelly
   • Ronan Swords
   • Francis J. Giles

   Review 21 April 2009 Pages: 99 - 105

7. Skin toxicities associated with epidermal growth factor receptor inhibitors

   • Tianhong Li
   • Roman Perez-Soler

   Review 19 May 2009 Pages: 107 - 119

   

8. Renal toxicity of targeted therapies

   • Ronan J. Kelly
   • Bertrand Billemont
   • Olivier Rixe

   Review 06 May 2009 Pages: 121 - 133

   

9. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

   • Kamalesh Sankhala
   • Alain Mita
   • Monica Mita

   Review 21 April 2009 Pages: 135 - 142

   

10. Maximum tolerated dose: clinical endpoint for a bygone era?

    • Chris H. Takimoto

    Review 18 April 2009 Pages: 143 - 147